Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. - Wikidata - wikimedia - TriplyDB

Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

http://www.wikidata.org/entity/Q36760112

about

Angiotensin-converting enzyme inhibitors for congestive heart failure in children Angiotensin-converting enzyme inhibitors for congestive heart failure in children Congestive heart failure and converting enzyme inhibition: failure of current prognostic criteria for predicting subsequent renal insufficiency Efficacy and dosage of enalapril in congenital and acquired heart disease.Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction.Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial Angiotensin converting enzyme inhibitors in heart failure: how good are they?Role of ACE inhibitors in uncomplicated essential hypertension.ACE inhibitors for heart failure: a question of dose Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure.Cough associated with captopril and enalapril Factors influencing survival and mode of death in severe chronic ischaemic cardiac failure.Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects Mortality in heart failure: clinical variables of prognostic value Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine.Enalapril in African patients with congestive cardiac failure.Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure.Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction.Angiotensin converting enzyme inhibitors for hypertension and heart failure?Vascular tone in heart failure: the neuroendocrine-therapeutic interface Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.Left ventricular dysfunction and ventricular arrhythmias: reducing the risk of sudden death.Diagnosis and management of heart failure.Cough and angiotensin converting enzyme inhibition.Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.Antihypertensive and organ-protective effects of benazepril.The Three-Decade Long Journey in Heart Failure Drug Development.Therapeutic progress--review XXXIV. Congestive cardiac failure.The positive association of cough with angiotensin-converting enzyme inhibitors.Clinical implications for therapy: possible cardioprotective effects of ACE inhibition.The renin-angiotensin-aldosterone-system and right heart failure in congenital heart disease.Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.Enalapril: a long-acting angiotensin-converting enzyme inhibitor.The clinical use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure.

P2860

Q24188260-94A96882-98FB-456E-822B-41F9F37A3DAA Q24202598-F9FF0D51-1948-403F-B3E5-4ED44F72AC71 Q28328514-AB7142E6-9B60-4E3E-9564-4BB9455E251A Q28369543-72FB3533-FAF0-4FF9-B14A-78B6B89042BA Q28378632-84625120-5D6E-4291-B974-CE042C4576EE Q31863980-AFD91741-E01F-406D-B319-D70816F5CED3 Q33611333-16714AD6-D360-440D-89C9-945641FCD2CC Q33611888-11237178-E266-45E2-85E9-B07F29759695 Q33612739-8F4B83C1-70D9-485E-A857-F26104C3E2BB Q33614270-5F33D566-46D6-4164-A301-740D020492C6 Q33614305-38AE88D9-720E-4892-8D18-4F7E626BA110 Q33614319-31ABBEF4-CDAB-4CF8-A633-EEF15FBBC0DE Q33789930-3586E3E5-E083-4529-8479-8FC7A3B1A494 Q34070598-171D9F3D-4E3C-4C5D-8FFE-8BA9DE37B25E Q34117868-8839E211-03DC-43C5-B280-7146AB96F189 Q34118531-468F9A5F-D690-4950-8D88-B6242E8041CC Q34118615-E633F681-202F-4949-B354-0F02C9892240 Q34210098-06D8CE14-F6C0-4ADC-8234-0FCBA4C0604B Q34358032-C087C475-CA41-46B5-8D2F-62D001D7F0A8 Q34358252-61E9A144-36F1-4FEC-8EE3-7BF24C9478E3 Q34397493-337752E7-0A0F-478E-A7E5-50345D2C6F4C Q35088348-28452205-E73A-4184-8982-9554A429DA01 Q35888473-19F8DF39-7F2D-4E0F-97BD-6A94C2256102 Q35958231-733B4514-DA0E-4FB6-B396-DC17E21FDE04 Q35990307-5878AA57-2409-483F-9559-6B22162114C4 Q36808117-DED40D38-EFE6-4934-8F5C-85B3F48D9F4A Q36818647-1259D084-D982-4C07-9BF7-51D8908D4234 Q36832235-F7A7E039-6C14-472B-9171-4078D6FF67F8 Q36883992-1A841052-BF5F-4420-B93F-EE5312BC3E24 Q36896077-7B9C838E-7E0B-4B6C-B71E-943E148D3AAD Q37170615-5DFF415C-98B2-44E0-9911-092BBBB0610A Q37812376-E2BEF340-5D14-4E37-B5E5-811F2F07BB4B Q38558614-0930B490-67D3-4E72-8CD2-FBC13B8B63CA Q38606288-BB3E1600-B1C4-4B41-BC88-A86204DCA682 Q38635844-468CEF11-3328-486E-8B2F-452DE7B2E296 Q38747861-74B37122-6E12-47E8-ABFE-88066EEE76A3 Q38888906-26929CE6-F5B4-4CCF-A2C6-E74F05559C6D Q38965377-8357E450-5920-4EEC-95E7-23FD331B548B Q39177686-D109B733-BEEB-48A3-A37B-634E285B479E Q39510450-691945F5-E14E-4B8B-A30F-AFF82A8D7E18

P2860

Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

http://www.wikidata.org/entity/Q36760112

description

1985 nî lūn-bûn

@nan

1985年の論文

@ja

1985年論文

@yue

1985年論文

@zh-hant

1985年論文

@zh-hk

1985年論文

@zh-mo

1985年論文

@zh-tw

1985年论文

@wuu

1985年论文

@zh

1985年论文

@zh-cn

name

Effects of enalapril in heart ...... hormones, and metabolic state.

@ast

Effects of enalapril in heart ...... hormones, and metabolic state.

@en

type

label

Effects of enalapril in heart ...... hormones, and metabolic state.

@ast

Effects of enalapril in heart ...... hormones, and metabolic state.

@en

prefLabel

Effects of enalapril in heart ...... hormones, and metabolic state.

@ast

Effects of enalapril in heart ...... hormones, and metabolic state.

@en

P1433

Q36760112-29D76175-3691-4AD7-9A3D-81ACC8249223

P1476

Q36760112-9EF52BCA-0AE5-44F5-9F9F-0C3764589FB5

P2093

Q36760112-0891ED0B-58C9-43E3-9A1C-3F9BCF5299E5

Q36760112-4894F92C-14F9-4158-AFE6-46937C7C5D23

Q36760112-59C04859-7C0A-4454-BCDB-782C9C2A3033

Q36760112-5FA8F646-D016-45EE-83C4-7E05C4E36E49

Q36760112-684C7045-8682-424B-9B6B-67793076FA56

Q36760112-ADE476C0-AD55-45F9-94F7-64E33D24C0AF

Q36760112-D1B54F79-1253-4064-AC86-FFD8BA68E87F

Q36760112-D46A266C-4985-4284-A980-E15A2959B9C5

Q36760112-DAD0C572-5210-483F-816E-3D5A9FA09125

Q36760112-DD0A5D13-F2CF-4025-A8E1-B8B3EADE07D3

P2860

Q36760112-018C9BCA-DEBE-402B-8EE8-8CD441E53169

Q36760112-06F00536-81C1-4603-B24E-E58840F62F7F

Q36760112-100B03A2-FC90-4F15-B2B9-8664E89FC903

Q36760112-1492A615-CF81-4F6C-9CF8-D9DFB0D89902

Q36760112-19286D0C-B004-4B70-A7C3-75B4AB43A8EC

Q36760112-2C50469B-59E6-45BC-A2FE-CDF986D19803

Q36760112-2E5CDA23-8835-4A99-A332-FCE628BF5736

Q36760112-38FEE04E-CE92-45AE-9925-BA76296FCF30

Q36760112-393F7C6F-8747-4C3A-B2A2-99B751F1C716

Q36760112-3B4FC4DD-84A3-4B25-9B9C-B78B25E1737A

P304

Q36760112-CF41702E-B899-4542-AC36-BF16BD1C356A

P31

Q36760112-8072DD4A-06C7-41F2-9FBE-B8B9F993AE4C

P356

Q36760112-68CD3B6E-E38D-4439-800E-183D2E0208C6

P433

Q36760112-EE54A79F-9412-4553-A788-44ADC12E3ACB

P478

Q36760112-FFBBEC40-AF18-4B45-8D67-CFCE134638DA

P577

Q36760112-03F822A3-1442-4DF7-8FEF-A775F56A0138

P5875

Q36760112-94F4C86F-9645-4C92-95B7-87FB03E5C1CE

P698

Q36760112-7CEB67BB-2EF4-4E8C-B975-8C0C8941BB4E

P921

Q36760112-B3D3A6C0-8533-464F-A13F-78A26D6A822E

P932

Q36760112-6A863F7A-A460-42C4-836B-D17E1E50B4BE

P356

P1433

British heart journal

P1476

Effects of enalapril in heart ...... hormones, and metabolic state.

@en

P2093

Ball SG

http://www.w3.org/2001/XMLSchema#string

Cleland JG

http://www.w3.org/2001/XMLSchema#string

Dargie HJ

http://www.w3.org/2001/XMLSchema#string

East BW

http://www.w3.org/2001/XMLSchema#string

Ford I

http://www.w3.org/2001/XMLSchema#string

Gillen G

http://www.w3.org/2001/XMLSchema#string

Hodsman GP

http://www.w3.org/2001/XMLSchema#string

Morton JJ

http://www.w3.org/2001/XMLSchema#string

Robertson I

http://www.w3.org/2001/XMLSchema#string

Robertson JI

http://www.w3.org/2001/XMLSchema#string

P2860

Captopril in the treatment of clinical hypertension and cardiac failure

Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin

Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.

Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study.

Factors related to first dose hypotensive effect of captopril: prediction and treatment.

Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease

The relation of total body potassium to height, weight, and age in normal adults.

Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure

Captopril in heart failure. A double blind controlled trial

Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.

P304

305-312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HRT.54.3.305

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

1985-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20160976

http://www.w3.org/2001/XMLSchema#string

P698

2994698

http://www.w3.org/2001/XMLSchema#string

P921

P932

481900

http://www.w3.org/2001/XMLSchema#string